GlassScriptPhysician profile
Joe E Rogers
NPI 1134698491
$5,558.62
in general payments reported to CMS, 2019-2025
40 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $826 · 2023: $1,722 · 2024: $1,505 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,732.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $925.43 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $482.87 | 2022-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $480.69 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $464.83 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $453.28 | 2022-2025 | |
| Abbvie INC. | $320.55 | 2022-2025 | |
| Glaxosmithkline, LLC. | $245.48 | 2023-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.65 | 2022-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $170.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $165.69 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $155.96 | 2022-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $145.69 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $114.62 | 2023-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $95.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Melinta Therapeutics, LLC | $86.64 | 2023 | Kimyrsa |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $86.19 | 2024 | Korlym |
| Axsome Therapeutics, INC. | $71.71 | 2022-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $67.03 | 2025 | Gemtesa |
| Eisai INC. | $63.94 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $62.71 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.33 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $56.46 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $54.88 | 2022-2023 | Crysvita |
| Dexcom, INC. | $50.31 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $44.78 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $44.37 | 2022-2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $42.43 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $38.28 | 2023-2024 | Nexletol |
| Astellas Pharma US INC | $38.02 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $28.17 | 2022-2025 | Zoryve |
| Abbott Laboratories | $27.17 | 2025 | Octrode |
| Seqirus USA INC | $26.83 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Genzyme Corporation | $22.78 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.71 | 2024 | |
| Grifols USA, LLC | $20.10 | 2022 | |
| Lundbeck LLC | $19.91 | 2023 | Rexulti |
| Boston Scientific Corporation | $19.57 | 2024 | General Dbs |
| Medtronic, INC. | $17.35 | 2024 | Minimed 780g |
| Pfizer INC. | $15.69 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.